Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

NACompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Smoking Cessation
Interventions
BEHAVIORAL

Standard Care (SC)

"1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."

BEHAVIORAL

Intensive Counseling (IC)

"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."

Trial Locations (3)

10065

Memorial Sloan-Kettering Cancer Center, New York

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Massachusetts General Hospital

OTHER

NCT01871506 - Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial | Biotech Hunter | Biotech Hunter